ReviewFrontiers in oncology2014
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 71 citations in OpenAlex.
- Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.Annals of hematology · 2015Trial
- IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma.Journal of experimental & clinical cancer research : CR · 2026Article
- Myeloid-Derived Suppressor Cells (MDSCs) Suppress T-Cell Proliferation Less Than Mature Neutrophils in Blood and Bone Marrow From Multiple Myeloma Patients.Journal of immunology research · 2026Article
- Article
- Progress of immune senescence in multiple myeloma treatment resistance.Discover oncology · 2025Review
- An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.Nature immunology · 2024Article
- Role of Immune Cells and Immunotherapy in Multiple Myeloma.Life (Basel, Switzerland) · 2024Review
- Article
- Dual roles of CD11bFrontiers in immunology · 2024Article
- Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma.British journal of haematology · 2023Article
- Therapeutic strategies to enhance immune response induced by multiple myeloma cells.Frontiers in immunology · 2023Review
- Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.Frontiers in immunology · 2023Review
- Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?International journal of molecular sciences · 2022Review
- Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma.Cancers · 2022Review
- The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.Frontiers in immunology · 2022Review
- Granulocytic myeloid-derived suppressor cells increase infection riskFrontiers in immunology · 2022Article
- Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma.NPJ precision oncology · 2021Article
- Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.Cancers · 2021Review
- Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.International journal of molecular sciences · 2021Article
- Natural Killer Cells in the Malignant Niche of Multiple Myeloma.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressive cells have been reported to play an important role in tumor-progression mainly because of their capability to promote immune-escape, angiogenesis, and metastasis. Among them, myeloid-derived suppressor cells (MDSCs) have been recently identified as immature myeloid cells, induced by tumor-associated inflammation, able to impair both innate and adaptive immunity. While murine MDSCs are usually identified by the expression of CD11b and Gr1, human MDSCs represent a more heterogeneous population characterized by the expression of CD33 and CD11b, low or no HLA-DR, and variable CD14 and CD15. In particular, the last two may alternatively identify monocyte-like or granulocyte-like MDSC subsets with different immunosuppressive properties. Recently, a substantial increase of MDSCs has been found in peripheral blood and bone marrow (BM) of multiple myeloma (MM) patients with a role in disease progression and/or drug resistance. Pre-clinical models recapitulating the complexity of the MM-related BM microenvironment (BMM) are major tools for the study of the interactions between MM cells and cells of the BMM (including MDSCs) and for the development of new agents targeting MM-associated immune-suppressive cells. This review will focus on current strategies for human MDSCs generation and investigation of their immunosuppressive function in vitro and in vivo, taking into account the relevant relationship occurring within the MM-BMM. We will then provide trends in MDSC-associated research and suggest potential application for the treatment of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.